Answers are grounded in this paper and cite their sources.
Pediatric cholestatic liver diseases, such as Alagille syndrome and progressive familial intrahepatic cholestasis, are rare genetic disorders characterized by impaired bile flow, systemic bile acid accumulation, and debilitating pruritus. Historically managed with supportive care or invasive surgical interventions, the therapeutic landscape has recently expanded with the introduction of ileal bile acid transporter (IBAT) inhibitors. These luminal, ileum-targeted agents block bile acid reabsorption, thereby increasing fecal bile acid excretion and effectively reducing the systemic bile acid pool to relieve pruritus. However, this pharmacological blockade also attenuates the intestinal farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) feedback loop, leading to a compensatory increase in hepatic bile acid synthesis. Consequently, the clinical efficacy and safety of IBAT inhibitors are heavily dependent on a sufficiently preserved enterohepatic bile flow and canalicular export capacity. When luminal bile acid delivery is impaired, therapeutic benefits diminish, and the unchecked compensatory synthesis may contribute to hepatocyte stress and elevated transaminases. Thus, optimizing the use of these therapies will require a shift from broad disease-label indications toward precision, genotype- and physiology-informed patient selection, utilizing non-invasive biomarkers to assess target engagement and guide clinical management.
No takes yet. Share an insight, caveat, or question.
Buduo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: